Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pircher

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
Clinical Genitourinary Cancer|July 2, 2018
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk PatientsRenate Pichler, Josef Fritz, Felizian Lackner, et al.
Plos One|August 11, 2018
The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targetsNormann Steiner, Udo Müller, Roman Hajek, et al.
Trends in Cancer|February 15, 2024
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLCLena Horvath, Constanze Puschmann, Alexandra Scheiber, et al.
Critical Reviews in Oncology/Hematology|July 10, 2020
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)Finn Mildner, Sieghart Sopper, Arno Amann, et al.
Anticancer Research|August 27, 2011
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancerAndreas Pircher, Ernst Ulsperger, Rene Hack, et al.
Preventive Veterinary Medicine|July 12, 2020
Koi herpesvirus disease outbreak: Input for the implementation of a surveillance program in South Tyrol - ItalyStefano Colorio, Anna Toffan, Eva Lewisch, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 25, 2013
Novel therapeutic approaches for the treatment of castration-resistant prostate cancerIsabel Heidegger, Petra Massoner, Iris E Eder, et al.
Journal for Immunotherapy of Cancer|November 7, 2022
Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospectsMaximilian Boesch, Lena Horvath, Florent Baty, et al.
Thrombosis and Haemostasis|October 28, 2010
Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasmsMichael Medinger, Alexandar Tzankov, Johann Kern, et al.
Translational Lung Cancer Research|February 11, 2021
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)Florian Kocher, Arno Amann, Kai Zimmer, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Clinical Genitourinary Cancer|July 2, 2018
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk PatientsRenate Pichler, Josef Fritz, Felizian Lackner, et al.
Plos One|August 11, 2018
The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targetsNormann Steiner, Udo Müller, Roman Hajek, et al.
Trends in Cancer|February 15, 2024
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLCLena Horvath, Constanze Puschmann, Alexandra Scheiber, et al.
Critical Reviews in Oncology/Hematology|July 10, 2020
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)Finn Mildner, Sieghart Sopper, Arno Amann, et al.
Anticancer Research|August 27, 2011
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancerAndreas Pircher, Ernst Ulsperger, Rene Hack, et al.
Preventive Veterinary Medicine|July 12, 2020
Koi herpesvirus disease outbreak: Input for the implementation of a surveillance program in South Tyrol - ItalyStefano Colorio, Anna Toffan, Eva Lewisch, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 25, 2013
Novel therapeutic approaches for the treatment of castration-resistant prostate cancerIsabel Heidegger, Petra Massoner, Iris E Eder, et al.
Journal for Immunotherapy of Cancer|November 7, 2022
Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospectsMaximilian Boesch, Lena Horvath, Florent Baty, et al.
Thrombosis and Haemostasis|October 28, 2010
Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasmsMichael Medinger, Alexandar Tzankov, Johann Kern, et al.
Translational Lung Cancer Research|February 11, 2021
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)Florian Kocher, Arno Amann, Kai Zimmer, et al.
Pageof 10